Meet the participants
Real Stories. Real Science. Real Time. Meet the companies selected to take part in The Hive - Elsevier's new program for startups that provides complimentary access to Elsevier’s suite of solutions to power their R&D. Follow The Hive to read their accounts of discovery and development fueled by access to the world’s top research solutions.
Arctic Pharma AS
Aiming to be a leader in environmentally friendly cancer therapies that have few side effects, Arctic Pharma AS is a start-up company developing innovative anti-cancer drugs by exploiting the
sweet tooth of cancer cells. The company targets key enzymes that are upregulated in cancer cell metabolism using inhibitors designed by them. This enables them to develop new pharmaceuticals with fewer side effects to combat cancer.
Myelo Therapeutics is a Germany-based pharmaceuticals company that develops innovative treatments in areas of high unmet medical needs.The company’s lead compound, Myelo001 – the first new therapy option for chemotherapy-induced neutropenia (CIN) in over 20 years – is currently being investigated in a clinical trial.
Reset Therapeutics is a discovery-stage biopharma company developing first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. Reset’s pipeline includes new chemical entities designed to treat Cushing’s disease, type-2 diabetes and other metabolic disorders and narcolepsy and other disorders associated with excessive daytime sleepiness.
Rubius Therapeutics is using breakthrough science to develop a new class of drugs, Red-Cell Therapeutics™ (RCTs), with the potential to address many areas of human disease, including metabolic conditions, autoimmune disorders, cancer and infectious diseases. Using its rapid prototyping capability, the company has already generated more than 150 different RCT prototypes and is in the process of validating the most promising candidates for clinical entry.
Learn More About Elsevier R&D Solutions for
Early Stage Drug Discovery and Development:
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Reduce time spent monitoring, organizing and annotating scientific and medical literature for triage and compliance reports such as PSURs and ICSRs.
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Drive pharmaceutical research towards innovative directions by working with Elsevier's Professional Services team to resolve challenges with data quality and integration.
Get meaningful answers to complex pharma R&D research questions through Elsevier's custom Text Mining service that enables the retrieval of highly specified information from unstructured content.
Enable researchers to more effectively and efficiently search authoritative, fulltext scientific, technical and health content through the use of smart, intuitive functionality.
Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peerreviewed literature, including tools to track, analyze and visualize research.